# US 2012/0252006 A1 · Methods and Systems for Multiple Control Validation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252006 A1
- Document ID: US20120252006A1
- Status: Published application
- Kind: A1
- Application number: 13/426,140
- Filed: 2012-03-21
- Published: 2012-10-04
- Earliest claimed: 2011-03-21
- Assignees: Laboratory Corporation of America Holdings
- Inventors: Elizabeth M. Rohlfs; Nicole Evan Castro
- Web page: https://patentgrep.com/patent/US20120252006A1

## CPC

- C12Q 1/6832: Enhancement of hybridisation reaction
- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides methods for validating a multiplex binding assay that results in a reduced number of false invalidations. The invention further provides systems for validating a multiplex binding assay that results in a reduced number of false invalidations. The invention further provides a computer readable medium containing program instructions for validating a multiplex binding assay that results in a reduced number of false invalidations.

## Claims

### Claim 1

A method for validating a multiplex binding assay, the method comprising:
(a) providing a binding assay having two or more sets of binding structures, wherein each set of binding structures comprises at least one target-adapted binding structure that is adapted to couple to a target analyte;
(b1) contacting a first set of the two or more sets of binding structures with a first negative control solution; and then (b2) determining a binding signal for the at least one target-adapted binding structure from the first set of two or more binding structures;
(c1) contacting a second set of the two or more sets of binding structures with a second negative control solution; and then (c2) determining a binding signal for the at least one target-adapted binding structure from the second set of two or more binding structures; and
(d) comparing each determined binding signal, or a value representative thereof, to a predetermined threshold and a predetermined limit to determine whether the binding assay is validated.

### Claim 2 (depends on 1)

The method of claim 1, wherein each binding structure is on the outer surface of a bead.

### Claim 3 (depends on 2)

The method of claim 2, wherein each bead has a diameter of 1 μm to 500 μm.

### Claim 4 (depends on 1)

The method of claim 1, wherein the target analyte is a polynucleotide, an oligonucleotide, a polypeptide, an oligopeptide, an antibody, an antibody fragment, a small-molecule organic compound, a metabolite of a small-molecule organic compound, a virus, or a pathogen.

### Claim 5 (depends on 4)

The method of claim 4, wherein the target analyte is a polynucleotide.

### Claim 6 (depends on 5)

The method of claim 5, wherein the analyte is a polynucleotide comprising a target-specific nucleotide sequence that includes a mutation that is indicative of an inherited disease or indicative of a vulnerability to an inherited disease.

### Claim 7 (depends on 6)

The method of claim 6, where the inherited disease is familial hypercholesterolenemia, polycystic kidney disease, neurofibromatosis type 1, neurofibromatosis type 2, hereditary spherocytosis, Marfan syndrome, Huntington's disease, sickle cell anemia, cystic fibrosis, lysosomal acid lipase (LAL) deficiency, Tay-Sachs disease, phenylketonuria, mucopolysaccharidoses, glycogen storage diseases, galactosemia, Duchenne muscular dystrophy, hemophilia, hereditary nonpolyposis colorectal cancer, hereditary multiple exostoses, Niemann-Pick disease, spinal muscular atrophy, Roberts syndrome, X-linked phosphatemic rickets, Rett syndrome, incontinentia pigmenti type 2, Aicardi syndrome, Klinefelter syndrome, Lesch-Nyhan syndrome, male pattern baldness, Turner syndrome, hypertrichosis pinnae, Leber's hereditary optic neuropathy, asthma, ciliopathies, cancers, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive disorder, or infertility.

### Claim 8 (depends on 4)

The method of claim 4, where the target analyte is a polynucleotide comprising a PCR-amplified region of the DNA of a human subject, where the PCR-amplified region includes one or more mutations that are indicative of an inherited disease or indicative of a vulnerability to an inherited disease.

### Claim 9 (depends on 8)

The method of claim 8, where the inherited disease is familial hypercholesterolenemia, polycystic kidney disease, neurofibromatosis type 1, neurofibromatosis type 2, hereditary spherocytosis, Marfan syndrome, Huntington's disease, sickle cell anemia, cyctic fibrosis, lysosomal acid lipase (LAL) deficiency, Tay-Sachs disease, phenylketonuria, mucopolysaccharidoses, glycogen storage diseases, galactosemia, Duchenne muscular dystrophy, hemophilia, hereditary nonpolyposis colorectal cancer, hereditary multiple exostoses, Niemann-Pick disease, spinal muscular atrophy, Roberts syndrome, X-linked phosphatemic rickets, Rett syndrome, incontinentia pigmenti type 2, Aicardi syndrome, Klinefelter syndrome, Lesch-Nyhan syndrome, male pattern baldness, Turner syndrome, hypertrichosis pinnae, Leber's hereditary optic neuropathy, asthma, ciliopathies, cancers, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive disorder, or infertility.

### Claim 10 (depends on 1)

The method of claim 1, wherein the target analyte is indicative of a likelihood of resistance to a drug-based therapy.

### Claim 11

A method for validating a multiplex binding assay, the method comprising:
(a) providing a binding assay having two or more sets of binding structures, wherein each set of binding structures comprises at least one target-adapted binding structure of a first type that is adapted to couple to a first target analyte, and at least one target-adapted binding structure of a second type that is adapted to couple to a second target analyte;
(b1) contacting a first set of the two or more sets of binding structures with a first negative control solution; and then (b2) determining a binding signal for the at least one target-adapted binding structure of the first type from the first set of two or more binding structures, and a binding signal for the at least one target-adapted binding structure of the second type from the first set of two or more binding structures;
(c1) contacting a second set of the two or more sets of binding structures with a second negative control solution; and then (b2) determining a binding signal for the at least one target-adapted binding structure of the first type from the second set of two or more binding structures, and a binding signal for the at least one target-adapted binding structure of the second type from the second set of two or more binding structures; and
(d) comparing each determined binding signal, or a value representative thereof, to a predetermined threshold and a predetermined limit to determine whether the binding assay is validated.

### Claim 12 (depends on 11)

The method of claim 11, wherein each binding structure is on the outer surface of a bead.

### Claim 13 (depends on 12)

The method of claim 12, wherein each bead has a diameter of 1 μm to 500 μm.

### Claim 14 (depends on 11)

The method of claim 11, wherein each of the first target analyte and the second target analyte is a polynucleotide, an oligonucleotide, a polypeptide, an oligopeptide, an antibody, an antibody fragment, a small-molecule organic compound, a metabolite of a small-molecule organic compound, a virus, or a pathogen.

### Claim 15 (depends on 14)

The method of claim 14, wherein each of the first target analyte and the second target analyte is a polynucleotide.

### Claim 16 (depends on 15)

The method of claim 15, wherein each of the first target analyte and the second target analyte is a polynucleotide comprising a target-specific nucleotide sequence that includes a mutation that is indicative of an inherited disease or indicative of a vulnerability to an inherited disease.

### Claim 17 (depends on 16)

The method of claim 16, where the inherited disease is familial hypercholesterolenemia, polycystic kidney disease, neurofibromatosis type 1, neurofibromatosis type 2, hereditary spherocytosis, Marfan syndrome, Huntington's disease, sickle cell anemia, cyctic fibrosis, lysosomal acid lipase (LAL) deficiency, Tay-Sachs disease, phenylketonuria, mucopolysaccharidoses, glycogen storage diseases, galactosemia, Duchenne muscular dystrophy, hemophilia, hereditary nonpolyposis colorectal cancer, hereditary multiple exostoses, Niemann-Pick disease, spinal muscular atrophy, Roberts syndrome, X-linked phosphatemic rickets, Rett syndrome, incontinentia pigmenti type 2, Aicardi syndrome, Klinefelter syndrome, Lesch-Nyhan syndrome, male pattern baldness, Turner syndrome, hypertrichosis pinnae, Leber's hereditary optic neuropathy, asthma, ciliopathies, cancers, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive disorder, or infertility.

### Claim 18 (depends on 14)

The method of claim 14, where each of the first target analyte and the second target analyte is a polynucleotide comprising a PCR-amplified region of the DNA of a human subject, where the PCR-amplified region includes one or more mutations that are indicative of an inherited disease or indicative of a vulnerability to an inherited disease.

### Claim 19 (depends on 18)

The method of claim 18, where the inherited disease is familial hypercholesterolenemia, polycystic kidney disease, neurofibromatosis type 1, neurofibromatosis type 2, hereditary spherocytosis, Marfan syndrome, Huntington's disease, sickle cell anemia, cyctic fibrosis, lysosomal acid lipase (LAL) deficiency, Tay-Sachs disease, phenylketonuria, mucopolysaccharidoses, glycogen storage diseases, galactosemia, Duchenne muscular dystrophy, hemophilia, hereditary nonpolyposis colorectal cancer, hereditary multiple exostoses, Niemann-Pick disease, spinal muscular atrophy, Roberts syndrome, X-linked phosphatemic rickets, Rett syndrome, incontinentia pigmenti type 2, Aicardi syndrome, Klinefelter syndrome, Lesch-Nyhan syndrome, male pattern baldness, Turner syndrome, hypertrichosis pinnae, Leber's hereditary optic neuropathy, asthma, ciliopathies, cancers, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive disorder, or infertility.

### Claim 20 (depends on 11)

The method of claim 11, wherein each of the first target analyte or the second target analyte is indicative of a likelihood of resistance to a drug-based therapy.

### Claim 21

A system for validating a multiplex binding assay having two or more sets of binding structures wherein each set of binding structures comprises at least one target-adapted binding structure that is adapted to couple to a target analyte, the system comprising:
(a) a station for contacting a first set of the two or more sets of binding structures with a first negative control solution;
(b) a station for contacting a second set of the two or more sets of binding structures with a second negative control solution;
(c) a station for determining a binding signal for the at least one target-adapted binding structure from the first set of two or more binding structures;
(d) a station for determining a binding signal for the at least one target-adapted binding structure from the second set of two or more binding structures; and
(e) a station for comparing each determined binding signal, or a value representative thereof, to a predetermined threshold and a predetermined limit to determine whether the binding assay is validated.

### Claim 22

A system for validating a multiplex binding assay having two or more sets of binding structures, wherein each set of binding structures comprises at least one target-adapted binding structure of a first type that is adapted to couple to a first target analyte, and at least one target-adapted binding structure of a second type that is adapted to couple to a second target analyte, the system comprising:
(a) a station for contacting a first set of the two or more sets of binding structures with a first negative control solution;
(b) a station for contacting a second set of the two or more sets of binding structures with a second negative control solution;
(c) a station for determining a binding signal for the at least one target-adapted binding structure of the first type from the first set of two or more binding structures, and a binding signal for the at least one target-adapted binding structure of the second type from the first set of two or more binding structures;
(d) a station for determining a binding signal for the at least one target-adapted binding structure of the first type from the second set of two or more binding structures, and a binding signal for the at least one target-adapted binding structure of the second type from the second set of two or more binding structures; and
(c) a station for comparing each determined binding signal, or a representative value thereof, to a predetermined threshold and a predetermined limit to determine whether the binding assay is validated.

### Claim 23

A computer readable medium for validating a multiplex binding assay, the computer readable medium comprising:
(a) program code for determining a binding signal for a target-adapted binding structure, where the target-adapted binding structure is a binding structure that is adapted to couple to a target analyte and subsequently contacted with a first negative control solution;
(b) program code for determining a binding signal for a target-adapted binding structure, where the target-adapted binding structure is a binding structure that is adapted to couple to a target analyte and subsequently contacted with a second negative control solution;
(c) program code for comparing each determined binding signal, or a value representative thereof, to a predetermined threshold and a predetermined limit; and
(d) program code for determining whether to determine whether the multiplex binding assay is validated.

### Claim 24

A computer readable medium for validating a multiplex binding assay, the computer readable medium comprising:
(a) program code for determining a binding signal for a target-adapted binding structure of a first type, where the target-adapted binding structure is a binding structure that is adapted to couple to a first target analyte and subsequently contacted with a first negative control solution;
(b) program code for determining a binding signal for a target-adapted binding structure of a second type, where the target-adapted binding structure is a binding structure that is adapted to couple to a second target analyte and subsequently contacted with a first negative control solution;
(c) program code for determining a binding signal for a target-adapted binding structure of a first type, where the target-adapted binding structure is a binding structure that is adapted to couple to a first target analyte and subsequently contacted with a second negative control solution;
(d) program code for determining a binding signal for a target-adapted binding structure of a second type, where the target-adapted binding structure is a binding structure that is adapted to couple to a second target analyte and subsequently contacted with a second negative control solution;
(e) program code for comparing each determined binding signal, or a value representative thereof, to a predetermined threshold and a predetermined limit; and
(f) program code for determining whether the multiplex binding assay is validated.
